|
Market Closed -
Nasdaq
16:00:00 2026-09-02 EDT
|
5-day change | 1st Jan Change | ||
| 11.23 USD | +1.45% |
|
+0.99% | -44.84% |
| 08-11 | BofA Securities Adjusts Keros Therapeutics Price Target to $17 From $20 | MT |
| 08-03 | Keros Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Compared values
| Sector | Change | 5-day change | YTD change | 1-year change | 5-year change | Capi. | ST | MT | LT | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KEROS THERAPEUTICS, INC. | Bio Therapeutic Drugs | +1.45% | +0.99% | -44.84% | -28.56% | -66.65% | 219M |  |  |  |
- Stock Market
- Stocks
- KROS Stock
- Charts Keros Therapeutics, Inc.
- Comparison Chart
Select your edition
All financial news and data tailored to specific country editions
